Mark Ziirsen – Chairman

Former Director Finance and IT, Asia Pacific at Cochlear Limited (ASX:COH) and Chief Financial Officer of Admedus Limited (ASX: AHZ). Mark is a highly strategic senior finance leader with proven commercial acumen. He brings to Respiri a strong track record of delivering growth and significant improvement across multiple industry sectors and geographies in executive roles with market leading international organisations. His strong credentials in finance strategy and business performance management are complemented by extensive corporate finance, governance, risk management, strategy, M&A and investor relations skills. Mark is a Non-Executive Director and Chair of the Audit Committee of ASX listed SmartTrans Holdings Limited.

Qualifications: B.Comm, Business/Commerce, General, University of Queensland, MBA, International Business, University of New England (AU)
 

Mario Gattino – CEO, Director

Mr Gattino is an internationally networked and award winning senior executive with 25+ years’ experience in pivotal ‘C’ suite leadership roles, realigning underperforming enterprises with comprehensive change leadership, crisis management and organisational turnaround expertise.

His experience is highly influenced by a distinguished 20 year career at Pfizer Inc. contributing to a long successful track record in commercialising drug and device products globally and growing sales in multiple markets including the USA, Europe and Asia. Taking on business critical international roles in complex commercial and sociopolitical environments, executing sophisticated corporate refocus, high-performance teambuilding and extensive stakeholder liaison of all major regulatory agencies (FDA,EMEA, TGA etc…) to deliver resounding profitability and viability.

Mr Gattino is a specialist in executive leadership and crisis management supported by high-caliber strategic planning and operational execution in complex project management, brand commercialisation, global portfolio execution, business development via M&A and licensing plus sophisticated stakeholder management.

Qualifications: MBA (Distinction) and Graduate Diploma in Management, University of New South Wales (Australian Graduate School of Management), Bachelor’s Degree Applied Science (Medical Administration) La Trobe University, Graduate (GAICD) Australian Institute of Company Directors, Executive Leadership Program, Harvard Business School.

 

Brendan Mason – Non-Executive Director

A med-tech and China market entry specialist, leading Cochlear Limited (ASX:COH) entry into Greater China as General Manager from 2007 to 2014. Brendan was responsible for market development, sales, marketing, distribution, regulatory affairs, customer support, IP protection and clinical trials for the Greater China region. He oversaw rapid growth of the business through drivers that required funding and reimbursement, infrastructure development and increasing consumer awareness through managing key opinion leaders and key government stakeholders. Previously, Brendan worked at Lucent as the Executive Director responsible for Telstra, Lucent’s largest account in Asia. He is a past board member, treasurer, and chairman of the Australian Chamber of Commerce, Beijing, where he established the government relations committee to provide advice to Chinese government and Australian member companies. Brendan Mason is the Non-Executive Director of Australia China Technology Incubator a federal government funded program for MedTech companies who aspire to export. Brendan is currently CEO and Managing Director of ASX listed SmartTrans Holdings Limited.

Qualifications: Post Graduate Diploma in Operations, Business Operations, University Prize for Excellence in Strategy, Macquarie University, EMBA Business Administration and Management, General, Australian Graduate School of Management

 

Scientific & Medical Advice

Respiri has worked with a number of globally respected physicians and scientists including, but not limited to:

Professor Noam Gavriely
An international authority on pulmonary acoustics, Prof Gavriely has extensively published on breath sound monitoring over the last 25 years and holds multiple patents on phonopneumography and other aspects of breath sound monitoring.

Professor Simon Godfrey
Emeritus Professor Pediatrics at the Hadassah-Hebrew University, Jerusalem, Prof Godfrey’s main research interests are in pediatric pulmonary physiology and application of novel investigative techniques for the diagnosis and management of pediatric pulmonary disease. He has published over 190 original papers and 16 books.

Professor Zahra Moussavi
Director, Biomedical Engineering Program Professor & Canada Research Chair University of Manitoba, Prof Moussavi specialises in sleep apnea, respiratory sounds analysis and Alzheimer’s diagnosis and treatment. She has published more than 180 papers.

Dr David Danztker
An internationally recognised expert in pulmonary medicine and critical care Dr Dantzker has served on the faculty and in leadership positions of four major research-oriented medical schools and authored or co-authored 130 research papers and five textbooks. He is former Chair of the American Board of Internal Medicine, the largest physician certifying board in the US.

Dr Catherine Downes
Dr Downes is a General Practitioner who has practiced in London and Australia. She has been a Principal of several large medical centres in Queensland and currently practice in a Sydney CBD medical centre. Dr Downes has also served as a Government Medical Officer in Queensland and attended Magistrate, District and Supreme courts as an expert medical witness.